Immucell (ICCC) Cash from Investing Activities (2010 - 2025)
Immucell's (ICCC) quarterly Cash from Investing Activities came in at -$167306.0 in Q4 2025, up 14.73% YoY from -$145821.1 in Q4 2024, and up 71.74% on a QoQ basis from -$592024.0 in Q3 2025.
Immucell (ICCC) Cash from Investing Activities (2010 - 2025) Analysis & Trends
Immucell (ICCC) has 16 years of Cash from Investing Activities data on file, last reported at -$167306.0 in Q4 2025.
- Quarterly Cash from Investing Activities rose 14.73% year-over-year to -$167306.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.2 million (down 163.28% YoY) and the FY2025 annual result came in at -$1.2 million, down 163.28% from the prior year.
- Cash from Investing Activities advanced to -$167306.0 in Q4 2025, from -$592024.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $656684.0 in Q1 2021 to a low of -$1.5 million in Q4 2022.
- A 5-year average of -$456360.2 and a median of -$562641.5 in 2023 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities surged 102.27% — and 2024, when it sank 680.81%.
- Tracing ICCC's Cash from Investing Activities over 5 years: stood at -$703279.0 in 2021, then tumbled by 111.89% to -$1.5 million in 2022, then surged by 102.27% to $33783.0 in 2023, then slumped by 680.81% to -$196216.0 in 2024, then grew by 14.73% to -$167306.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$167306.0 (Q4 2025), -$592024.0 (Q3 2025), and -$125927.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Immucell | 91.19 Mn | 82.33 Mn | 2.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -167,306.00 |
| Dec 31, 2025 | -167,306.00 |
| Sep 30, 2025 | -592,024.00 |
| Sep 30, 2025 | -592,024.00 |
| Jun 30, 2025 | -125,927.00 |
| Jun 30, 2025 | -125,927.00 |
| Mar 31, 2025 | -329,050.00 |
| Mar 31, 2025 | -329,050.00 |
| Dec 31, 2024 | -196,216.00 |
| Dec 31, 2024 | -196,216.00 |
| Sep 30, 2024 | -88,412.00 |
| Sep 30, 2024 | -88,412.00 |
| Jun 30, 2024 | -106,241.00 |
| Jun 30, 2024 | -106,241.00 |
| Mar 31, 2024 | -70,356.00 |
| Mar 31, 2024 | -70,356.00 |
| Dec 31, 2023 | 33,783.00 |
| Dec 31, 2023 | 33,783.00 |
| Sep 30, 2023 | -533,259.00 |
| Sep 30, 2023 | -533,259.00 |